Tripelennamine

Tripelennamine

Clinical data
AHFS/Drugs.com	Multum Consumer Information
MedlinePlus	a601044
Routes of administration	Oral, Intravenous
ATC code	D04AA04 (WHO) R06AC04 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Metabolism	Hepatic hydroxylation and glucuronidation
Biological half-life	4-6 hours
Excretion	Renal
Identifiers
IUPAC name N,N-dimethyl-N-(phenylmethyl)-N-pyridin-2-ylethane-1,2-diamine
CAS Number	91-81-6 Y
PubChem CID	5587
IUPHAR/BPS	7318
DrugBank	DB00792 Y
ChemSpider	5385 Y
UNII	3C5ORO99TY
KEGG	D08645 Y
ChEMBL	CHEMBL1241 Y
ECHA InfoCard	100.001.910
Chemical and physical data
Formula	C16H21N3
Molar mass	255.358 g/mol
3D model (Jmol)	Interactive image
SMILES CN(C)CCN(CC1=CC=CC=C1)C2=NC=CC=C2
InChI InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3 Y Key:UFLGIAIHIAPJJC-UHFFFAOYSA-N Y

Tripelennamine (sold as Pyribenzamine by Novartis) is a drug that is used as an antipruritic and first-generation antihistamine. It can be used in the treatment of asthma, hay fever, rhinitis and urticaria, but is now less common as it has been replaced by newer antihistamines.

Where and when it is/was in common use, tripelennamine is used much like other mildly-anticholinergic antihistamines for treating conditions of the upper respiratory tract arising from illnesses and hay fever. It can be used alone or in combination with other agents to have the desired effect. Cough medicine of the general formula tripelennamine + codeine/dihydrocodine/hydrocodone ± expectorant ± decongestant(s) is quite popular where available. One example is the line of Pyribenzamine Cough Syrups which contains codeine and with and without decongestants listed in the 1978 Physicians' Desk Reference; the codeine-tripelennamine synergy is well-known and does make such mixtures more useful for their intended purposes.

Tripelennamine is mildly sedating. Other side effects can include irritation, dry mouth, nausea, and dizziness.

Tripelennamine acts primarily as an antihistamine, or H₁ receptor antagonist. It has little to no anticholinergic activity. In addition to its antihistamine properties, tripelennamine also acts as a weak serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). Because of its SRI properties, tripelennamine was used as the basis for the development of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Luvox).